https://www.selleckchem.com/pr....oducts/mi-3-menin-ml
003). Molecular responses remained stable in 69.0%, improved in 25.5%, and worsened in 5.5% of patients. AEs were similar in the pre- and post-switch periods; however, a significant difference was found in favor of generic imatinib for muscular cramps ( 0.0001), periorbital edema ( =0.0028), edema of the limbs ( 0.0001), fatigue ( =0.0482), and diarrhea ( =0.0027). Our data indicate that generic imatinib does not have deleterious effects on CML control and present an acceptable safety profile, similar or better
Like
Comment
Share
